Vascular versus myocardial effects of calcium antagonists

W C Little1, C P Cheng

  • 1Department of Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.

Drugs
|January 1, 1994
PubMed

Insights

Felodipine, a calcium channel blocker, demonstrates high vascular selectivity, causing vasodilation without negative inotropic effects. Unlike other calcium antagonists, felodipine enhances myocardial relaxation and filling, indicating superior vasoselectivity.

Area of Science:

  • Cardiovascular Pharmacology
  • Calcium Channel Blockers
  • Myocardial Contractility

Background:

  • Calcium entry is crucial for vascular smooth muscle tone and myocardial contractility.
  • Calcium antagonists are potent vasodilators but may have negative inotropic effects.
  • Verapamil affects vascular and myocardial contraction similarly, while felodipine shows high vascular selectivity.

Purpose of the Study:

  • To evaluate the inotropic effects of felodipine in conscious dogs.
  • To compare the vasoselectivity of felodipine with amlodipine and nifedipine.
  • To determine if felodipine exhibits negative inotropic effects at clinically relevant doses.

Main Methods:

  • Utilized left ventricular (LV) pressure-volume analysis in conscious dogs.
  • Administered felodipine at a plasma concentration of 16 nmol/L.
  • Conducted studies with and without adrenergic blockade.

Main Results:

  • Felodipine caused a 25 mm Hg fall in arterial pressure and reduced peripheral vascular resistance by 10%.
  • No negative inotropic effects were observed; myocardial contractile performance was slightly enhanced.
  • Felodipine improved LV relaxation and early diastolic filling, unlike amlodipine and nifedipine.

Conclusions:

  • Felodipine exhibits significantly greater vasoselectivity compared to amlodipine and nifedipine.
  • Clinically relevant doses of felodipine do not appear to have negative inotropic effects.
  • Felodipine's unique profile enhances myocardial relaxation and diastolic filling.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...